Ophthalmology and Eye Disorders

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the pathophysiology, management, and associated conditions of Graves' ophthalmopathy, including the role of thyroid-associated ophthalmopathy, orbital fibroblasts, thyrotropin receptor antibodies, teprotumumab treatment, autoimmune mechanisms, thalamus infarction, surgical interventions for strabismus, and the involvement of the IGF-1 receptor. The research covers a wide range of topics related to the understanding and treatment of Graves' ophthalmopathy.

163

Works

IDs:OpenAlex

How has Ophthalmology and Eye Disorders's publication output changed over time?

ScholarIQpublication output · 2005–2020

Output grew0% over the shown period — from 1 works in 2005 to 1 in 2020.

2005200820102013201420152017201820192020

What are the most-cited papers on Ophthalmology and Eye Disorders?

ScholarIQmost cited works

Teprotumumab for Thyroid-Associated Ophthalmopathy

Terry J. Smith, George J. Kahaly, Daniel G. Ezra, James C. Fleming, Roger A. Dailey, Rosa A. Tang, Gerald J. Harris, Alessandro Antonelli, Mario Salvi, Robert A. Goldberg, James W. Gigantelli, Steven M. Couch, Erin M. Shriver, Brent Hayek, Eric M. Hink, Richard M. Woodward, Kathleen Gabriel, Guido Magni, Raymond S. Douglas

New England Journal of Medicine. 2017733 CitationsOPEN ACCESS

Randomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy

Marius N. Stan, James A. Garrity, Barbara Gisella Carranza Leon, Thapa Prabin, Elizabeth A. Bradley, Rebecca S. Bahn

The Journal of Clinical Endocrinology & Metabolism. 2014358 CitationsOPEN ACCESS

New insights into the pathogenesis and nonsurgical management of Graves orbitopathy

Peter Taylor, Lei Zhang, Richard Lee, Ilaria Muller, Daniel G. Ezra, Colin Dayan, George J. Kahaly, Marian Ludgate

S116269268. 2019315 CitationsOPEN ACCESS

Risk Factors for Development or Deterioration of Graves' Ophthalmopathy

Marius N. Stan, Rebecca S. Bahn

Thyroid. 2010230 CitationsOPEN ACCESS

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

George J. Kahaly, Michaela Riedl, J. König, Susanne Pitz, Katharina A. Ponto, Tanja Diana, Elena Kampmann, E. W. Kolbe, Anja Eckstein, Lars C. Moeller, Dagmar Führer, Mario Salvi, Nicola Currò, Irene Campi, Danila Covelli, Marenza Leo, Michele Marinò, Francesca Menconi, Claudio Marcocci, Luigi Bartalena, Petros Perros, Wilmar M. Wiersinga, Göksün Ayvaz, Lelio Baldeschi, Kostas Boborides, Antonella Boschi, Thomas Heiberg Brix, Lucy Clarke, Colin Dayan, Chantal Daumerie, A. Jane Dickinson, N. Fichter, László Hegedüs, Onur Konuk, Gerassimos Krassas, Carol Lane, John H. Lazarus, Dan S Morris, Maarten P. Mourits, Marco Nardi, C Neoh, Jacques Orgiazzi, Simon H. S. Pearce, Georg von Arx, Miloš Žarković

The Lancet Diabetes & Endocrinology. 2018219 Citations